NEW YORK, Nov. 21, 2008 (GLOBE NEWSWIRE) -- Veteran business journalist Sasha Salama joins Mr. Thomas Lynch, Chairman and Chief Executive Officer, Amarin Corporation plc (Nasdaq:AMRN), to discuss the company's industry, strategy, financials and positioning.
Click here to view video: http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=34352&k=860C8936EA2E0ADEDC5ED8550A82B1CD
Mr. Thomas Lynch joined Amarin in January 2000 as Chairman and Non-Executive Director and was appointed Chief Executive Officer in 2007. Between 1993 and 2004, Mr. Lynch was with Elan Corporation plc where he held a number of positions including Chief Financial Officer and Executive Vice Chairman. Mr. Lynch spearheaded Elan's transition from a drug delivery technology provider to a fully integrated pharmaceutical company through a number of acquisitions, including Athena Neurosciences, Inc. The Athena acquisition brought Elan its programs in multiple sclerosis, autoimmune diseases and Alzheimer's disease. Mr. Lynch was also a founder of the specialty pharmaceutical company Warner Chilcott plc. Mr. Lynch is and has been a board member of a number of biotechnology and healthcare companies. Mr. Lynch was a partner in the international accounting firm of KPMG, where he specialized in the provision of international corporate financial services.
About Amarin Corporation plc
Amarin is a clinical-stage biopharmaceutical company with a lead program entering Phase 3 for hypertriglyceridemia. Amarin's cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin's pipeline also includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease and epilepsy, all of which are available for partnering. Amarin is listed in the U.S. on the NASDAQ Capital Market ("AMRN"). For more information please visit www.amarincorp.com.
The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839
For more information about NASDAQ CEO Signature Series interviews, call 978/461-3141.